

### CLAIMS

- 12
- 5 1.- A pharmaceutical preparation of microcapsules of lactic-co-glycolic copolymer which incorporates a peptide of pharmaceutical interest, characterised in that the copolymer that forms the microcapsules incorporates a citric acid ester as an additive.
2. A pharmaceutical preparation of microcapsules according to claim 1 characterised in that the citric acid ester is selected from triethyl citrate, tributyl citrate and acetyl tributyl citrate.
3. A pharmaceutical preparation of microcapsules according to claim 2 characterised in that the citric acid ester is triethyl citrate.
- 30 4. A preparation according to claim 3 characterised in that the amount of triethyl citrate contained in the preparation varies between 0.1% and 60% by weight of the copolymer.
5. A pharmaceutical preparation according to claims 1 to 4 characterised in that the percentage ratio between the lactate and glycolate units in the lactic-co-glycolic copolymer varies between 100% and lactate and 90% of glycolate, both inclusive.
- 15 6. A pharmaceutical preparation according to any of the previous claims characterised in that the encapsulated peptide of pharmaceutical interest is an analogue of LHRH.
7. A pharmaceutical preparation according to claim 6 characterised in that the analogue of LHRH is selected from tryptoreline, leuprolide, gosereline, busereline or cetrotorelix.
- 20 8. A pharmaceutical preparation according to claims 1 to 5 characterised in that the encapsulated peptide of pharmaceutical interest is somatostatin or an analogue thereof.
9. A pharmaceutical preparation according to claim 8 characterised in that the analogue of somatostatin is octreotide.
10. A pharmaceutical preparation according to claims 1 to 5 characterised in that the encapsulated peptide of pharmaceutical interest is an analogue of human calcitonin.
- 25 11. A pharmaceutical preparation according to claim 10 characterised in that the analogue of human calcitonin is salmon calcitonin or carbonylcalcitonin.